EHA2021 Virtual Congress

Mitapivat Induces Responses in Patients With Thalassemia

Researchers sought to determine whether mitapivat would improve clinical outcomes in patients with thalassemias who are not transfusion-dependent.

First-in-Human Results Show Promise With BT200, a New Anti-von Willebrand Factor Agent

Researchers sought to determine whether BT200, a new anti-von Willebrand factor, would have efficacy in patients with von Willebrand disease.

Belumosudil Yields Clinically Meaningful Outcomes in Patients With Chronic Graft-Vs-Host Disease

Researchers sough to determine whether belumosudil would help treat patients with chronic GVHD.

Positive Results Seen With Voxelotor in Pediatric Patients With Sickle Cell Disease

Researchers sought to determine whether the use of voxelotor in a younger population of patients with sickle cell disease would be safe and effective.

Iptacopan Shows Promise in First Line Treatment of Paroxysmal Nocturnal Hemoglobinuria

Researchers sought to determine whether iptacopan would have efficacy in first line treatment of patients with PNH.

Lower Mutation Burden With Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Patients With Myelodysplastic Syndromes

Researchers sought to determine whether pevonedistat plus azacitidine would result in a lower residual mutation load than seen with azacitidine alone in patients with MDS.

Iberdomide-Based Regimens Show Promise in Relapsed/Refractory Multiple Myeloma

The median duration of response was 35.7 weeks with iberdomide, bortezomib, and dexamethasone compared with not reached in patients who received iberdomide, daratumumab, and dexamethasone or iberdomide, bortezomib, and carfilzomib

Long-Term Follow-Up Data Support Adding Daratumumab to Lenalidomide/Dexamethasone in Transplant-Ineligible MM

The median progression-free survival was not reached in the D-Rd group compared with 34.4 months in the Rd group.

Continued Benefit Observed With Isatuximab Plus Pomalidomide and Dexamethasone in Multiple Myeloma

Adding isatuximab to pomalidomide and dexamethasone improved progression-free survival (PFS) and PFS2.

CLL/SLL: Ibrutinib, Venetoclax Therapy May Improve Outcomes in First Line

The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.

Relapsed, Refractory Follicular Lymphoma: CAR-T Cell Therapy Shows Promise

In patients who had received at least 2 prior therapy lines, the overall response rates were 49.9% in SCHOLAR-5 vs 94.2% in ZUMA-5.

DLBCL: Naratuximab Shows Promise Among Patients With Relapsed/Refractory Disease

The overall response rate was 44.7% after a median follow-up of 15 months.

MATRIX Provides ‘Excellent, Long-Lasting Survival’ in Primary CNS Lymphoma

The 7-year survival results were superior with MATRIX.

Tislelizumab Deemed an ‘Important Option’ for Relapsed/Refractory Classical Hodgkin Lymphoma

The median overall survival was not reached at 3 years.

Brentuximab Vedotin-Based Regimens Show Long-Term Safety, Efficacy in Classical Hodgkin Lymphoma

The 3-year overall survival rate was 95% with one regimen and 100% with the other.

Anti-CD20 Therapy Linked to Prolonged Hospital Stay and Death in Lymphoma Patients With COVID-19

Relapsed/refractory disease and older age were also associated with prolonged hospital stay and death.

Non-Hodgkin Lymphoma: Copanlisib Rituximab Combination May Improve Survival

Six patients experienced a grade 5 treatment-related adverse event.

At-Home Chemotherapy Appears Safe, Feasible for Acute Myeloid Leukemia, Myelodysplastic Syndromes

Roughly a quarter of treatment cycles were administered solely as home-based treatment, with no hospital admissions required.

CML: COVID-19 May Be Fatal in More Than 5% of Patients

The mortality rate was 0.13% in the overall chronic myeloid leukemia cohort.

Tisagenlecleucel Appears Effective in Babies With Advanced B-Cell Acute Lymphoblastic Leukemia

The 12-month overall survival rate was 88%.